{"title":"肺动脉高压的当前和未来药物治疗","authors":"Jennifer A. Johnson, A. Hemnes","doi":"10.4137/CMT.S2108","DOIUrl":null,"url":null,"abstract":"Pulmonary arterial hypertension (PAH) is a progressive disease leading to obstruction of the small pulmonary arteries. Currently, there are eight approved medications for PAH. This review article focuses on the mechanisms, clinical trials, efficacy, and safety profiles of each of the PAH medications. In addition, this review addresses combination PAH therapy, patient preference, and future therapies.","PeriodicalId":10428,"journal":{"name":"Clinical Medicine and Therapeutics","volume":"44 1","pages":"1307-1316"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"present and prospective pharmacotherapies in pulmonary Arterial Hypertension\",\"authors\":\"Jennifer A. Johnson, A. Hemnes\",\"doi\":\"10.4137/CMT.S2108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pulmonary arterial hypertension (PAH) is a progressive disease leading to obstruction of the small pulmonary arteries. Currently, there are eight approved medications for PAH. This review article focuses on the mechanisms, clinical trials, efficacy, and safety profiles of each of the PAH medications. In addition, this review addresses combination PAH therapy, patient preference, and future therapies.\",\"PeriodicalId\":10428,\"journal\":{\"name\":\"Clinical Medicine and Therapeutics\",\"volume\":\"44 1\",\"pages\":\"1307-1316\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/CMT.S2108\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/CMT.S2108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
present and prospective pharmacotherapies in pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease leading to obstruction of the small pulmonary arteries. Currently, there are eight approved medications for PAH. This review article focuses on the mechanisms, clinical trials, efficacy, and safety profiles of each of the PAH medications. In addition, this review addresses combination PAH therapy, patient preference, and future therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
